Eisai Co., Ltd. (ESAIY)
OTCMKTS · Delayed Price · Currency is USD
7.11
+0.02 (0.28%)
Aug 1, 2025, 3:58 PM EDT
Eisai Employees
Eisai had 10,917 employees as of March 31, 2025. The number of employees decreased by 150 or -1.36% compared to the previous year.
Employees
10,917
Change (1Y)
-150
Growth (1Y)
-1.36%
Revenue / Employee
$482,873
Profits / Employee
$28,402
Market Cap
8.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 10,917 | -150 | -1.36% |
Mar 31, 2024 | 11,067 | -9 | -0.08% |
Mar 31, 2023 | 11,076 | -246 | -2.17% |
Mar 31, 2022 | 11,322 | 85 | 0.76% |
Mar 31, 2021 | 11,237 | 239 | 2.17% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
CytoDyn | 9 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Eisai News
- 2 days ago - Patients still benefit from Eisai and Biogen Alzheimer's drug after four years, study finds - Reuters
- 7 weeks ago - Eisai: Leqembi Approved In EU (Rating Downgrade) - Seeking Alpha
- 2 months ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 5 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 5 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 6 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters